Breaking News Instant updates and real-time market news.

STZ

Constellation Brands

$164.10

-0.03 (-0.02%)

, EA

Electronic Arts

$90.68

-1.82 (-1.97%)

10:17
01/22/19
01/22
10:17
01/22/19
10:17

Fly Intel: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Constellation Brands (STZ) initiated with an Overweight at Atlantic Equities. 2. Take-Two (TTWO) initiated with a Buy at Deutsche Bank, while Electronic Arts (EA) and Activision Blizzard (ATVI) were initiated with a Hold. 3. Insys Therapeutics (INSY) initiated with an Overweight at Cantor Fitzgerald. 4. Heico (HEI) initiated with a Buy at Vertical Research. 5. R1 RCM (RCM) initiated with an Overweight at KeyBanc. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

STZ

Constellation Brands

$164.10

-0.03 (-0.02%)

EA

Electronic Arts

$90.68

-1.82 (-1.97%)

TTWO

Take-Two

$107.79

-0.45 (-0.42%)

ATVI

Activision Blizzard

$47.38

-1.26 (-2.59%)

INSY

Insys Therapeutics

$4.45

0.03 (0.68%)

HEI

Heico

$79.07

-1.23 (-1.53%)

RCM

R1 RCM

$8.17

-0.15 (-1.80%)

  • 24

    Jan

  • 05

    Feb

  • 06

    Feb

  • 12

    Feb

  • 18

    Feb

  • 25

    Feb

STZ Constellation Brands
$164.10

-0.03 (-0.02%)

01/22/19
ATLE
01/22/19
INITIATION
ATLE
Overweight
Constellation Brands initiated with an Overweight at Atlantic Equities
Yesterday, Atlantic Equities initiated Constellation Brands wian an Overweight and $227 price target.
01/10/19
01/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Constellation Brands (STZ) upgraded to Buy from Neutral at Goldman Sachs and to Neutral from Sell at Guggenheim. 2. Boeing (BA) upgraded to Overweight from Equal Weight at Morgan Stanley. 3. Lockheed Martin (LMT) upgraded to Buy from Hold at Vertical Group. 4. United Continental (UAL) upgraded to Overweight from Neutral at JPMorgan while Alaska Air (ALK) was upgraded to Neutral from Underweight. 5. Twitter (TWTR) double upgraded to Buy from Underperform at BofA/Merrill with analyst Justin Post citing a survey he conducted which showed Twitter penetration increased to 48% of respondents and the percentage of users reporting deceased usage fell slightly. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/11/19
ARGS
01/11/19
NO CHANGE
Target $210
ARGS
Buy
Constellation Brands price target lowered to $210 from $260 at Argus
Argus analyst John Staszak lowered his price target on Constellation Brands to $210 after its "disappointing guidance" after the company cut its FY19 EPS outlook to $9.20-$9.30 from $9.60-$9.75 "based on rising interest expense and expectations for a slight slowdown in the wine and spirits segment." The analyst also lowers his FY19 EPS view to $9.70 from $9.80 but contends that the selloff is "overdone" as Constellation Brands shares trade at an "attractive valuation" relative to its historical levels and its peer group.
01/17/19
JEFF
01/17/19
NO CHANGE
Target $258
JEFF
Buy
Constellation Brands remains top pick after beer update at Jefferies
Constellation Brands (STZ) "confidently outlined the attractive growth story still ahead" at its beer segment update in Chicago, Jefferies analyst Kevin Grundy tells investors in a research note. The analyst believes the positive tone on the company's "key value driver," which presents over 70% of its EBITDA, should "quell some concerns that have contributed to recent dislocation in the stock." Constellation's beer business remains healthy while the Canopy Growth (CGC) stake in now a free call option, writes Grundy. The stock remains his top pick with a Buy rating and $258 price target.
EA Electronic Arts
$90.68

-1.82 (-1.97%)

01/22/19
DBAB
01/22/19
INITIATION
Target $100
DBAB
Hold
Electronic Arts initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Bryan Kraft started Electronic Arts with a Hold rating and $100 price target.
01/17/19
JEFF
01/17/19
DOWNGRADE
Target $95
JEFF
Hold
Jefferies downgrades Electronic Arts to Hold, cuts target to $95 from $139
Jefferies analyst Timothy O'Shea downgraded Electronic Arts to Hold from Buy and lowered his price target for the shares to $95 from $139. The company's key profit engine Ultimate Team is plateauing, O'Shea tells investors in a research note. Further, with a string of "mixed-reviewed" non-sports games, namely Mass Effect, Need for Speed and Star Wars Battlefront II, Electronic Arts "has a lot to prove as it brings a slate of unproven titles to market in 2019," says the analyst. He expects year-over-year operating income margin compression of 300 basis points in fiscal 2019 and views consensus earnings estimates as aggressive.
01/22/19
PIPR
01/22/19
NO CHANGE
PIPR
NPD video game sales declined 4% in December, says Piper Jaffray
Overall December NPD video game sales declined 4% year-over-year, but was up 2% for the full December quarter, Piper Jaffray analyst Michael Olson tells investors in a research note. Red Dead Redemption 2 from Take-Two (TTWO), Activision's (ATVI) Black Ops 4 and Nintendo's Super Smash Bros. Ultimate were the top titles for the quarter, Olson adds. He maintains Overweight ratings on Activision Blizzard, Take-Two and Electronic Arts (EA).
01/17/19
01/17/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Electronic Arts (EA) downgraded to Hold from Buy at Jefferies with analyst Timothy O'Shea saying the company's key profit engine Ultimate Team is plateauing. 2. First Data (FDC) downgraded to Neutral from Buy at Goldman Sachs and Mizuho, to Neutral from Overweight at Atlantic Equities, and to Market Perform from Outperform at Keefe Bruyette. 3. PulteGroup (PHM) downgraded to Sell from Neutral at BTIG with analyst Carl Reichardt citing valuation, sell-side optimism, and growing margin pressure. 4. Aegon (AEG) downgraded to Sell from Neutral at Citi. 5. Patterson-UTI (PTEN) downgraded to Neutral from Overweight at JPMorgan with analyst Sean Meakim saying while the company's Q4 rig count exceeded guidance, its exposure to smaller Exploration & Production companies increases its potential rig losses in 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TTWO Take-Two
$107.79

-0.45 (-0.42%)

01/16/19
GABE
01/16/19
INITIATION
Target $136
GABE
Buy
Take-Two initiated with a Buy at Gabelli
Gabelli analyst initiated Take-Two with a Buy and Alec Boccanfuso $136 price target.
01/16/19
01/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mercantil Bank (AMTB) initiated with a Buy at SunTrust. 2. ViewRay (VRAY) initiated with a Buy at Guggenheim. 3. PTC (PTC) initiated with a Buy at Deutsche Bank. 4. Altice USA (ATUS) and Charter (CHTR) were initiated with a Buy at TD Securities. Charter (CHTR) was also initiated with a Neutral at Nomura Instinet. 5. Take-Two (TTWO) initiated with a Buy at Gabelli. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/22/19
DBAB
01/22/19
INITIATION
Target $130
DBAB
Buy
Take-Two initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Bryan Kraft started Take-Two Interactive Software with a Buy rating and $130 price target.
ATVI Activision Blizzard
$47.38

-1.26 (-2.59%)

01/22/19
DBAB
01/22/19
INITIATION
Target $54
DBAB
Hold
Activision Blizzard initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Bryan Kraft started Activision Blizzard with a Hold rating and $54 price target.
01/16/19
SPHN
01/16/19
NO CHANGE
Target $125
SPHN
Overweight
Stephens a buyer of Electronic Arts shares on Star Wars headline weakness
Stephens analyst Jeff Cohen noted that Kotaku reported that Electronic Arts (EA) has canceled its "Star Wars" open world game, which it will replace with a smaller "Star Wars" game. While he acknowledges the headlines will not help sentiment and will renew questions about the company's "Star Wars" license, Cohen does not view the news as a material negative and would be a buyer of EA shares on any weakness related to the report. Cohen, who also contends that the uncertainty around the Destiny franchise, which Activision Blizzard (ATVI) is returning to Bungie, could have a positive impact the release of EA's Anthem, keeps an Overweight rating and $125 price target on Electronic Arts shares.
01/15/19
BTIG
01/15/19
NO CHANGE
Target $63
BTIG
Buy
Activision Blizzard price target lowered to $63 from $88 at BTIG
BTIG analyst Brandon Ross lowered his price target on Activision Blizzard to $63 and also reduced his FY19 EPS view to $2.72 from $3.20 to reflect the retreat in consensus estimates after the company's "revealed weakness" in its Q3 earnings call. The analyst also points to the "uncertainty around Blizzard's release schedule and the severance of a deal with Bungie which meant the loss of the Destiny franchise". Longer term, Ross keeps his Buy rating on the stock and expects Activision Blizzard to re-accelerate growth next year as the management optimizes its cost structure while also pursuing a "large mobile opportunity", adding that its 2020 catalysts include Overwatch expansion and Diablo 4 launch.
INSY Insys Therapeutics
$4.45

0.03 (0.68%)

03/09/18
PIPR
03/09/18
DOWNGRADE
Target $4
PIPR
Underweight
Insys Therapeutics downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst David Amsellem downgraded Insys Therapeutics to Underweight and cut his price target for the shares to $4 from $5. The analyst sees "no basis in reality" for the company's guidance of relatively stable total sales in 2018 versus 2017 given the nature of the opioid crisis. Further, the weak rollout of Syndros "also does not inspire confidence" in the 2018 guidance, Amsellem tells investors in a research note.
01/22/19
CANT
01/22/19
INITIATION
Target $9
CANT
Overweight
Insys Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes started Insys Therapeutics with an Overweight rating and $9 price target. The analyst sees 2019 as a "pivotal and transformational year" for Insys with two potential filings with its spray platform along with two data readouts from its cannabinoids platform. 2019 could be the year in which investors are able to return to Insys and "appreciate the value which could be unlocked from within the company's spray and cannabinoids pipeline," Folkes tells investors in a research note.
12/19/18
JANY
12/19/18
INITIATION
Target $11
JANY
Buy
Insys Therapeutics assumed with a Buy at Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong assumed coverage of Insys Therapeutics with a Buy rating and fair value estimate of $11, down from the firm's prior $16 estimate. Zhong said Insys is shifting focus from commercializing opioid products to developing cannabinoids and proprietary spray technology, adding that he views the heated discussion during a two-day FDA AdCom on naloxone earlier this week as a "clear sign" for an increased commercial opportunity for Insys. Zhong also believes the data from the cannabidiol programs, if positive, could unlock significant upside potential.
08/10/18
PIPR
08/10/18
NO CHANGE
Target $4
PIPR
Underweight
Insys DOJ settlement does not remove downside risk, says Piper Jaffray
Piper Jaffray analyst David Amsellem says the settlement with the Department of Justice does not mean there isn't downside risk in shares of Insys Therapeutics. For a $600M market capitalization, investors are getting a sublingual form of buprenorphine that was "roundly rejected" by an FDA panel in May, a cannabidiol product that has yet to demonstrate proof-of-concept in a well-controlled trial, a product in Syndros that has minimal sales after approximately one year of active promotion, and a declining asset in Subsys that has limited profitability, Amsellem tells investors in a research note following Insys' Q2 results. The analyst does not believe the shares are "adequately risk-adjusted." He reiterates an Underweight rating on Insys with a $4 price target.
HEI Heico
$79.07

-1.23 (-1.53%)

08/29/18
ADAM
08/29/18
NO CHANGE
Target $100
ADAM
Buy
Heico price target raised to $100 from $84 at Canaccord
Canaccord analyst Ken Herbert raised his price target on Heico to $100 from $84 following better than expected Q3 results. The analyst said there is growing optimism that the recent IATA ruling on CFM engine competitive practices will create a new marketing opportunity for the company and he noted the organic growth, especially in the FSG segment, was encouraging. Herbert reiterated his Buy rating on Heico shares.
08/29/18
RHCO
08/29/18
NO CHANGE
Target $97
RHCO
Buy
Heico price target raised to $97 from $85 at SunTrust
SunTrust analyst Michael Ciarmoli raised his price target on Heico to $97 and kept his Buy rating after its "strong" Q3 results, saying the quarter "exceeded expectations on organic revenue growth acceleration" in both Flight Support Group and Electronic Technologies Group segments. The analyst expects sustained strength of defense and aftermarket demand to continue supporting the stock, adding that the latest pro-competition International Air Transport Association agreement with CFM will remove the overhang regarding Heico's total market expansion over the long term, even though Ciarmoli does not expect the benefits from this deal to materialize over the next 12-18 months.
08/29/18
JEFF
08/29/18
NO CHANGE
Target $100
JEFF
Buy
Heico price target raised to $100 from $86 at Jefferies
Jefferies analyst Sheila Kahyaoglu raised her price target for Heico to $100 after the company reported 12% organic growth in fiscal Q3. Heico appears well positioned to capitalize on expansion of its markets given product introductions and a proven acquisition strategy, Kahyaoglu tells investors in a post-earnings research note titled "Delivering Results Across the Portfolio." The analyst keeps a Buy rating on the shares.
01/22/19
VERT
01/22/19
INITIATION
Target $91
VERT
Buy
Heico initiated with a Buy at Vertical Research
Vertical Research initiated Heico with a Buy and $91 price target.
RCM R1 RCM
$8.17

-0.15 (-1.80%)

12/10/18
SBSH
12/10/18
INITIATION
Target $20
SBSH
Buy
R1 RCM initiated with a Buy at Citi
Citi analyst Stephanie Demko started R1 RCM with a Buy rating and $20 price target. The company operates as the largest independent end-to-end revenue cycle management provider in the U.S., and is well positioned to benefit from growing demand for provider-facing information technology, Demko tells investors in a research note.
01/22/19
KEYB
01/22/19
INITIATION
Target $10
KEYB
Overweight
R1 RCM initiated with an Overweight at KeyBanc
KeyBanc analyst Donald Hooker started R1 RCM with an Overweight rating and $10 price target as a way for investors to play what he expects will be an increasing trend of revenue cycle outsourcing by U.S. health systems. The analyst believes R1 RCM is a beat-and-raise story, benefiting from low consensus expectations and a large $80B-plus TAM.
09/04/18
CHDN
09/04/18
INITIATION
Target $17
CHDN
Buy
R1 RCM initiated with a Buy at Chardan
Chardan analyst Steven Wardell initiated R1 RCM with a Buy and $17 price target.
01/07/19
BARD
01/07/19
NO CHANGE
Target $11
BARD
Outperform
R1 RCM designated as a Fresh Pick at Baird
Baird analyst Matthew Gillmor designated R1 RCM as a Fresh Pick ahead of the company's presentation at the JP Morgan conference later this week. He believes it is likely the company will provide 2019 EBITDA guidance in-line with to ahead of Street expectations and thinks there could be a positive update with respect to its 2020 outlook. Gillmor reiterated his Outperform rating and $11 price target on R1 RCM shares.

TODAY'S FREE FLY STORIES

IFF

International Flavors

$122.54

-0.98 (-0.79%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
International Flavors rating change at Goldman Sachs »

International Flavors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

QRVO

Qorvo

$69.15

-0.93 (-1.33%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
Qorvo rating change at Goldman Sachs »

Qorvo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

ATI

Allegheny Technologies

$26.02

0.065 (0.25%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
Allegheny Technologies rating change at Goldman Sachs »

Allegheny Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$4.98

0.17 (3.53%)

21:33
03/20/19
03/20
21:33
03/20/19
21:33
Upgrade
Internap rating change at Wells Fargo »

Internap upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$108.62

-1.79 (-1.62%)

, CAG

Conagra Brands

$22.91

0.095 (0.42%)

20:25
03/20/19
03/20
20:25
03/20/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

DRI

Darden

$108.62

-1.79 (-1.62%)

CAG

Conagra Brands

$22.91

0.095 (0.42%)

CMC

Commercial Metals

$16.06

-0.06 (-0.37%)

GIII

G-III Apparel

$35.09

-0.475 (-1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

HYMTF

Hyundai Motor

$0.00

(0.00%)

19:51
03/20/19
03/20
19:51
03/20/19
19:51
Periodicals
Hyundai shareholders to vote on Elliott Management dividend demand, Reuters says »

Hyundai Motor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVBF

CVB Financial

$21.12

-0.53 (-2.45%)

19:45
03/20/19
03/20
19:45
03/20/19
19:45
Hot Stocks
CVB Financial raises quarterly dividend to 18c from 14c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KAMN

Kaman

$57.84

0.345 (0.60%)

19:24
03/20/19
03/20
19:24
03/20/19
19:24
Periodicals
Kaman exploring sale of distribution segment, Bloomberg says »

Kaman is looking into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

VALE

Vale

$13.49

-0.21 (-1.53%)

19:19
03/20/19
03/20
19:19
03/20/19
19:19
Hot Stocks
Vale suspends operations at Alegria mine in Mariana complex on preventive basis »

Vale S.A. informs that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

EQH

AXA Equitable

$20.84

-0.565 (-2.64%)

19:12
03/20/19
03/20
19:12
03/20/19
19:12
Syndicate
AXA Equitable 40M share Secondary priced at $20.50 »

JPMorgan, Morgan Stanley…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

OTTW

Ottawa Bancorp

$13.56

-0.14 (-1.02%)

19:02
03/20/19
03/20
19:02
03/20/19
19:02
Hot Stocks
Ottawa Bancorp declares special dividend of 35c per share »

The special dividend will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAZZ

Jazz Pharmaceuticals

$133.73

-1.74 (-1.28%)

18:57
03/20/19
03/20
18:57
03/20/19
18:57
Hot Stocks
Jazz Pharmaceuticals' Sunosi for excessive daytime sleepiness approved by FDA »

Jazz…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

AYI

Acuity Brands

$123.00

-5.53 (-4.30%)

18:52
03/20/19
03/20
18:52
03/20/19
18:52
Upgrade
Acuity Brands rating change at Goldman Sachs »

Acuity Brands upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Apr

HYAC

Haymaker Acquisition

$11.79

(0.00%)

, OSW

OneSpaWorld

$0.00

(0.00%)

18:47
03/20/19
03/20
18:47
03/20/19
18:47
Hot Stocks
OneSpaWorld says will start trading on Nasdaq March 21 »

OneSpaWorld Holdings…

HYAC

Haymaker Acquisition

$11.79

(0.00%)

OSW

OneSpaWorld

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$35.07

-0.85 (-2.37%)

, MU

Micron

$40.08

-0.3 (-0.74%)

18:46
03/20/19
03/20
18:46
03/20/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MLHR

Herman Miller

$35.07

-0.85 (-2.37%)

MU

Micron

$40.08

-0.3 (-0.74%)

WSM

Williams-Sonoma

$56.88

0.09 (0.16%)

SIEN

Sientra

$9.76

0.945 (10.73%)

EB

Eventbrite

$20.09

-0.72 (-3.46%)

GES

Guess

$22.10

-0.41 (-1.82%)

UNIT

Uniti Group

$10.01

0.15 (1.52%)

WEX

Wex

$184.85

-1.465 (-0.79%)

CBMG

Cellular Biomedicine

$18.26

0.38 (2.13%)

FTDR

Frontdoor

$32.10

-2.29 (-6.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 02

    Apr

  • 03

    Apr

  • 28

    May

  • 21

    Mar

  • 21

    Mar

SAGE

Sage Therapeutics

$152.62

-3.46 (-2.22%)

18:39
03/20/19
03/20
18:39
03/20/19
18:39
Hot Stocks
Sage Therapeutics CEO: Postpartum depression is a medical issue »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$174.38

-1.39 (-0.79%)

18:27
03/20/19
03/20
18:27
03/20/19
18:27
Recommendations
Nvidia analyst commentary at Tigress Financial »

Nvidia to overcome…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CURLF

Curaleaf Holdings

$0.00

(0.00%)

, CVS

CVS Health

$56.17

-0.93 (-1.63%)

18:24
03/20/19
03/20
18:24
03/20/19
18:24
Periodicals
CVS to start selling CBD products in partnership with Curaleaf, Bloomberg says »

Curaleaf (CURLF) said…

CURLF

Curaleaf Holdings

$0.00

(0.00%)

CVS

CVS Health

$56.17

-0.93 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

PETQ

PetIQ

$29.87

0.91 (3.14%)

18:23
03/20/19
03/20
18:23
03/20/19
18:23
Hot Stocks
PetIQ CEO: We are totally transparent about our price model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

T

AT&T

$30.51

-0.19 (-0.62%)

18:21
03/20/19
03/20
18:21
03/20/19
18:21
Periodicals
AT&T CEO: Huawei makes it hard for carriers to shift suppliers, Reuters says »

AT&T CEO Randall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 24

    Apr

  • 26

    Apr

  • 07

    May

  • 20

    May

SGSOY

SGS SA

$0.00

(0.00%)

18:19
03/20/19
03/20
18:19
03/20/19
18:19
Downgrade
SGS SA rating change at Goldman Sachs »

SGS SA downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLX

Clorox

$155.94

-0.93 (-0.59%)

, RBGLY

Reckitt Benckiser

$0.00

(0.00%)

18:16
03/20/19
03/20
18:16
03/20/19
18:16
Hot Stocks
Clorox files false advertising lawsuit against Reckitt Benckiser »

The Clorox Company (CLX)…

CLX

Clorox

$155.94

-0.93 (-0.59%)

RBGLY

Reckitt Benckiser

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

BA

Boeing

$376.41

2.54 (0.68%)

18:09
03/20/19
03/20
18:09
03/20/19
18:09
Periodicals
Boeing pushes flight test to International Space Station to August, Reuters says »

Boeing has postponed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 28

    May

CE

Celanese

$101.04

0.08 (0.08%)

18:02
03/20/19
03/20
18:02
03/20/19
18:02
Hot Stocks
Celanese increases acetyl intermeditates prices »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

FTDR

Frontdoor

$32.10

-2.29 (-6.66%)

17:58
03/20/19
03/20
17:58
03/20/19
17:58
Syndicate
Frontdoor 16.73M share Secondary priced at $30.00 »

JPMorgan and Goldman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.